Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies

被引:0
作者
Erika P. Navarro-Mendoza
Gabriel J. Tobón
机构
[1] Universidad Icesi,GIRAT: Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional, Fundación Valle del Lili
[2] Fundación Valle del Lili,Immunology Laboratory
来源
Current Rheumatology Reports | 2018年 / 20卷
关键词
Churg−Strauss syndrome; Therapeutics; Rituximab; Omalizumab; Mepolizumab;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 442 条
[1]  
Guillevin L(2013)2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides Arthritis Rheum 65 1-11
[2]  
Hagen EC(2005)Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome Arthritis Rheum 52 2926-2935
[3]  
Hoffman GS(2012)Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes J Allergy Clin Immunol 130 607-12.e9
[4]  
Jayne DR(2005)What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol 19 191-207
[5]  
Kallenberg CGM(2013)Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the art Allergy 68 261-273
[6]  
Lamprecht P(1951)Allergic granulomatosis, allergic angiitis, and periarteritis nodosa Am J Pathol 27 277-301
[7]  
Sinico RA(1995)Vasculitides associated with infections, immunization, and antimicrobial drugs Clin Infect Dis 20 1010-1036
[8]  
Di Toma L(2007)HLA–DRB4 as a genetic risk factor for Churg–Strauss syndrome Arthritis Rheum 56 3159-3166
[9]  
Maggiore U(2011)Both Th2 and Th17 responses are involved in the pathogenesis of Churg–Strauss syndrome Clin Exp Rheumatol 29 S23-S34
[10]  
Bottero P(2010)Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV) Clin Exp Rheumatol 28 62-66